SG11201909206XA - Macro-encapsulated therapeutic cells and methods of using the same - Google Patents
Macro-encapsulated therapeutic cells and methods of using the sameInfo
- Publication number
- SG11201909206XA SG11201909206XA SG11201909206XA SG11201909206XA SG 11201909206X A SG11201909206X A SG 11201909206XA SG 11201909206X A SG11201909206X A SG 11201909206XA SG 11201909206X A SG11201909206X A SG 11201909206XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- macro
- pct
- applicant
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- 240000004183 Bongardia chrysogonum Species 0.000 abstract 2
- 235000000914 Solidago virgaurea Nutrition 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 239000008188 pellet Substances 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000004888 barrier function Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/04—Alginic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482413P | 2017-04-06 | 2017-04-06 | |
| PCT/US2018/020446 WO2018186953A1 (en) | 2017-04-06 | 2018-03-01 | Macro-encapsulated therapeutic cells and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909206XA true SG11201909206XA (en) | 2019-11-28 |
Family
ID=61764135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909206X SG11201909206XA (en) | 2017-04-06 | 2018-03-01 | Macro-encapsulated therapeutic cells and methods of using the same |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11975031B2 (ja) |
| EP (1) | EP3606613A1 (ja) |
| JP (1) | JP7293126B2 (ja) |
| KR (1) | KR102572188B1 (ja) |
| CN (1) | CN110709137A (ja) |
| AU (1) | AU2018250008B2 (ja) |
| BR (1) | BR112019020611A2 (ja) |
| CA (1) | CA3058369A1 (ja) |
| IL (1) | IL269817B1 (ja) |
| RU (1) | RU2019131719A (ja) |
| SG (1) | SG11201909206XA (ja) |
| WO (1) | WO2018186953A1 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3092356A1 (en) * | 2018-03-01 | 2019-09-06 | Seraxis, Inc. | Macro-encapsulated therapeutic cells, devices, and methods of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743545A (en) * | 1984-08-09 | 1988-05-10 | Torobin Leonard B | Hollow porous microspheres containing biocatalyst |
| US5545423A (en) * | 1991-11-25 | 1996-08-13 | Vivorx, Inc. | Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials |
| US5334640A (en) * | 1992-04-08 | 1994-08-02 | Clover Consolidated, Ltd. | Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods |
| ES2179839T3 (es) | 1992-11-16 | 2003-02-01 | Univ Brown Res Found | Macrocapsulas microporosas. |
| PL376471A1 (en) * | 2002-10-11 | 2005-12-27 | Novocell, Inc. | Implantation of encapsulated biological materials for treating diseases |
| US20070237749A1 (en) * | 2006-04-07 | 2007-10-11 | Wang Taylor G | Multi-membrane immunoisolation system for cellular transplant |
| US20080292690A1 (en) * | 2006-04-07 | 2008-11-27 | Technology Center | Multi-membrane immunoisolation system for cellular transplant |
| WO2010032242A1 (en) * | 2008-09-17 | 2010-03-25 | Beta O2 Technologies Ltd. | Optimization of alginate encapsulation of islets for transplantation |
| KR101096902B1 (ko) * | 2009-01-15 | 2011-12-22 | 가톨릭대학교 산학협력단 | 당뇨병 치료용 알기네이트-키토산 이중막의 췌도 미세캡슐 및 이의 제조방법 |
| SG193615A1 (en) * | 2011-03-29 | 2013-11-29 | Beta Cell Nv | Method for encapsulated therapeutic products and uses thereof |
| KR101373518B1 (ko) * | 2011-04-28 | 2014-03-13 | 서울대학교산학협력단 | 췌도 캡슐 및 이의 제조 방법 |
| CA2940756A1 (en) * | 2013-11-07 | 2015-05-14 | The General Hospital Corporation | Eluting matrix and uses thereof |
| US9408807B2 (en) | 2015-01-13 | 2016-08-09 | Taylor Gun-Jin Wang | Semi-permeable encapsulation system with tapered conduits for diabetes reversal |
| JP2018521717A (ja) | 2015-05-17 | 2018-08-09 | マサチューセッツ インスティテュート オブ テクノロジー | 細胞および細胞凝集体を封入するための多層ヒドロゲルカプセル |
-
2018
- 2018-03-01 EP EP18713086.9A patent/EP3606613A1/en active Pending
- 2018-03-01 US US15/909,449 patent/US11975031B2/en active Active
- 2018-03-01 WO PCT/US2018/020446 patent/WO2018186953A1/en unknown
- 2018-03-01 CA CA3058369A patent/CA3058369A1/en active Pending
- 2018-03-01 JP JP2019554669A patent/JP7293126B2/ja active Active
- 2018-03-01 IL IL269817A patent/IL269817B1/en unknown
- 2018-03-01 KR KR1020197030643A patent/KR102572188B1/ko active IP Right Grant
- 2018-03-01 BR BR112019020611A patent/BR112019020611A2/pt not_active Application Discontinuation
- 2018-03-01 CN CN201880036340.6A patent/CN110709137A/zh active Pending
- 2018-03-01 AU AU2018250008A patent/AU2018250008B2/en active Active
- 2018-03-01 RU RU2019131719A patent/RU2019131719A/ru not_active Application Discontinuation
- 2018-03-01 SG SG11201909206X patent/SG11201909206XA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018250008B2 (en) | 2024-05-02 |
| US20180289746A1 (en) | 2018-10-11 |
| KR102572188B1 (ko) | 2023-08-30 |
| KR20190133708A (ko) | 2019-12-03 |
| RU2019131719A (ru) | 2021-05-06 |
| EP3606613A1 (en) | 2020-02-12 |
| CA3058369A1 (en) | 2018-10-11 |
| IL269817B1 (en) | 2024-03-01 |
| WO2018186953A1 (en) | 2018-10-11 |
| CN110709137A (zh) | 2020-01-17 |
| AU2018250008A1 (en) | 2019-10-31 |
| US11975031B2 (en) | 2024-05-07 |
| IL269817A (en) | 2019-11-28 |
| JP7293126B2 (ja) | 2023-06-19 |
| JP2020512999A (ja) | 2020-04-30 |
| BR112019020611A2 (pt) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201909009TA (en) | Catheter securement device with window | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201805942UA (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201908042TA (en) | Smartcard | |
| SG11201804721SA (en) | Modulators of complement activity | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201810618QA (en) | Depot formulations |